# A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

> **NCT05630066** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 48 (actual)

## Conditions studied

- Angelman Syndrome

## Interventions

- **DRUG:** Alogabat

## Key facts

- **NCT ID:** NCT05630066
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-27
- **Primary completion:** 2025-12-02
- **Final completion:** 2025-12-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630066, "A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05630066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*